Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Show more

Location: 540 Gaither Road, Rockville, MD, 20850, United States | Website: https://www.avalotx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

97.5M

52 Wk Range

$3.39 - $16.00

Previous Close

$9.00

Open

$9.01

Volume

148,096

Day Range

$8.51 - $9.88

Enterprise Value

5.854M

Cash

113.3M

Avg Qtr Burn

-11.85M

Insider Ownership

5.26%

Institutional Own.

66.87%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AVTX-803 (CERC-803) Details Leukocyte Adhesion Deficiency Type II	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-009 Details Hidradenitis suppurativa, Autoimmune disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quisovalimab/AVTX-002 (CERC-002) Details Asthma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quisovalimab/ AVTX-002 (CERC-002) Details COVID-19	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quisovalimab/ AVTX-002 (CERC-002) Details Crohns disease	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-007 (CERC-007) Details Multiple myeloma, Adult Onset Still's Disease	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-006 (CERC-006) Details Lymphatic malformations	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-801 (CERC-801) Details Metabolic disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-802 (CERC-802) Details Metabolic disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.